Compare First Trust NASDAQ Clean Edge Green Energy Idx Fd (QCLN) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust NASDAQ Clean Edge Green Energy Idx Fd vs Sana Biotechnology Inc — how do they compare? First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $53.03, while Sana Biotechnology Inc trades at $3.13 (market cap $879.40M). The key difference: First Trust NASDAQ Clean Edge Green Energy Idx Fd is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| QCLN | SANA | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $68.47 | $5.92 |
52-Week Low | $34.31 | $2.68 |
Market Cap | — | $879.40M |
Enterprise Value | — | $853.59M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QCLN trades at $51.25, down 1.9% with a bearish technical signal showing 17 sell indicators versus 3 buy signals. The ETF faces headwinds from regulatory uncertainty around renewable energy permits and supply chain pressures, though long-term growth prospects remain supported by rising data center energy demand and global clean energy investments. Technical analysis indicates strong resistance at $52-$56 with support at $48-$51.
The clean energy sector faces near-term policy risks but benefits from structural tailwinds. Investment appeal depends on resolution of US permit delays and China trade tensions, with current technical weakness suggesting cautious entry points may emerge near support levels for long-term positioning in the energy transition theme.
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About First Trust NASDAQ Clean Edge Green Energy Idx Fd
QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
